Recent 8-K filings for KEQU

• September 9, 2026, 4:19 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Kewaunee Q1 FY27 net earnings fall 45% to $1.7M; EPS $0.58 vs $1.04

  Sales $66.3M, down 6.7% YoY; pre-tax earnings $2.56M, down 34.7%.

• June 23, 2026, 5:10 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Kewaunee Scientific reports FY2026 revenue up 17.3% to $282M; EPS down to $3.22 from $3.83

  Full-year sales $281.999M (+17.3% YoY); net earnings $9.618M vs $11.405M prior year.

• March 11, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Kewaunee Scientific Q3 sales +3.3% to $69.4M; diluted EPS $0.23 vs $0.45; backlog down 17% YoY

  Sales $69.4M (+3.3% YoY); pre-tax earnings $1.6M (+25.8%).

• December 10, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Kewaunee Scientific Q2 FY2026: sales +46.8% to $70.1M, diluted EPS $0.82 vs $1.01

  Sales up 46.8% to $70.1M; net earnings $2.45M (-18.7%); diluted EPS $0.82 (vs $1.01).

• December 4, 2025, 6:59 PM ET debt materiality 0.70 positive item 1.01item 1.02item 2.03item 7.01item 9.01 ◈ Material Agreements ×2

  Kewaunee repays $23M seller notes early with new $10M term loan and revolver draw

  Entered First Amendment with PNC Bank for additional $10M term loan and revolver access to fund repayment.

• September 10, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Kewaunee Scientific Q1 sales up 47%; EPS $1.04; backlog $205M; expects FY EBITDA increase

  Sales $71.1M (+46.9% YoY); diluted EPS $1.04 vs $0.74; net earnings $3.09M.

• June 26, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Kewaunee Scientific Q4 sales up 36% to $77.1M; EPS $1.63, backlog $214.6M

  Q4 sales $77.1M, +36% YoY; pre-tax earnings $7.1M vs $1.3M prior year quarter (which included non-recurring pension charge).

• March 12, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Kewaunee Q3 revenue +44% to $67.2M; adj. diluted EPS $1.09 vs $0.85

  GAAP diluted EPS $0.45 vs $0.85; net earnings $1.4M vs $2.5M; includes $2.5M Nu Aire acquisition & integration costs.

• January 16, 2025, 6:59 PM ET M&A materiality 0.75 positive item 9.01

  Kewaunee closes Nu Aire acquisition for $55M; audited Nu Aire FY24 net income $5.44M

  Kewaunee acquired Nu Aire for $55M on Nov 1, 2024, using $35M bank financing and $23M seller notes at 8%.

• December 11, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Kewaunee Scientific Q2 FY2025: Sales down 5.3%, diluted EPS $1.01 vs $0.93 YoY; backlog record $184.4M

  Net sales $47.8M (down 5.3% YoY); domestic sales up 6.5%, international down 30.1% due to India construction delays.

• November 1, 2024, 7:59 PM ET M&A materiality 0.80 positive item 1.01item 2.01item 2.03item 7.01item 9.01 ◈ M&A Transactions

  Kewaunee Scientific acquires Nu Aire for $55M; expands life sciences product line

  Total purchase price $55M, funded with $32M cash (PNC revolver & term loan) and $23M seller notes at 8%.

• June 26, 2024, 7:59 PM ET earnings materiality 0.72 positive item 2.02item 9.01

  Kewaunee Q4 sales up 5%, adjusted EPS $1.55 vs $0.34; backlog rises to $155.6M

  Q4 sales $56.7M (+5% YoY); GAAP net earnings $11.0M (diluted EPS $3.71) include two non-recurring items.

• March 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Kewaunee Q3 FY2024 EPS $0.85 vs $0.25 YoY; net income triples despite 23% sales drop

  Sales $46.8M, down 23% YoY from $60.8M; net income $2.5M vs $0.7M.

• December 6, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Kewaunee Scientific swings to Q2 profit of $2.7M; EPS $0.93 vs -$0.09

  Sales $50.4M, down 7.6% YoY; net earnings $2.7M vs loss of $243K.

• September 1, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Kewaunee Scientific Q1 net earnings $2.47M vs loss of $0.75M YoY; EPS $0.86 vs ($0.27)

  Net earnings of $2.47M ($0.86 diluted EPS) vs net loss of $0.75M ($0.27 loss) in prior Q1.

• June 28, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Kewaunee Scientific posts Q4 profit of $0.34/share; FY revenue up 30% to $219.5M

  Q4 net earnings $1,005,000 ($0.34 diluted EPS) vs net loss of $362,000 ($0.13 loss) in prior year.

• March 8, 2023, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Kewaunee Q3 net income $723K ($0.25 EPS) vs loss; sales up 49.7%

  Net earnings $723K ($0.25 diluted EPS) vs net loss $1,319K (-$0.47); sales $60.8M, +49.7% YoY.

• December 8, 2022, 6:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01 ◈ Earnings Releases

  Kewaunee Scientific Q2 sales up 39.8% to $54.6M; net loss narrows to $0.09/share from $1.11

  Sales $54.6M (+39.8% YoY); pre-tax earnings $456k vs loss $2.9M; net loss $243k vs $3.1M.

• September 8, 2022, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  Kewaunee Scientific Q1 FY2023 net loss narrows to $0.27/share; sales up 27% YoY

  Sales $50.1M, up 26.9% YoY from $39.5M; net loss of $747K vs $1.35M loss a year earlier.

• June 30, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Kewaunee Q4 sales up 28.4% to $49.7M; backlog record $173.9M; full year loss widens

  Q4 sales $49.7M (+28.4% YoY); pre-tax earnings $2.3M vs loss $0.95M; EBITDA $2.97M vs -$0.30M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.47 · Most common event earnings

15 positive 2 negative 33 neutral

source · KEQU on sec.gov